You are here

Corinne Linardic

Associate Professor Pediatrics,
Pharmacology and Cancer Biology
(919) 681-3508
Research Interest: 
Cell cycle
Signal transduction
Research Summary: 
Mechanisms of sarcomagenesis; senescence; modeling cancer from primary human cells.
Research Description: 

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Despite international cooperative group clinical trials, survival for high risk groups remains less than 30% at 5 years. Our research group seeks to identify the molecular underpinnings for this poor survival, and exploit these findings to design new treatments. Current research themes including modeling RMS from non-malignant primary cells, understanding how developmental pathways including Notch and Wnt are hijacked to support RMS tumor initiation and maintenance, understanding how the PAX3-FOXO1 fusion protein in RMS enables bypass of senescence, and the role of the recently described Hippo organ size control pathway in RMS.

Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, Bentley RC, Galindo RL, Chi JT, Linardic CM.
J Clin Invest. 2014. 124:285-96.

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.
Clin Cancer Res. 2012. 18:3780-90.

Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea BC, Naini S, Bentley RC, Linardic CM.
Clin Cancer Res. 2011. 17:7324-36.

Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.
Crose LE, Linardic CM.
Sarcoma. 2011. 2011:756982.

Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.
Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM.
Cancer Res. 2008. 68:9583-8.